Jefferies reiterates Hana Biosciences at buy

Jefferies & Co., Inc. analyst Adam Walsh reiterated Hana Biosciences Inc. at a buy and a $16 price target on news of the company's phase 2 trial for Marqibo (sphingosomal encapsulated vincristine) in patients with relapsed or refractory acute lymphoblastic leukemia. With the start of the trial, the company completes another on-time milestone and expands the clinical pipeline, according to the analyst. Shares of the South San Francisco, Calif.-based biopharmaceutical company were down 1 cent, or 0.14%, at $7.32 on volume of 89,121 shares versus the three-month running average of 200,978 shares. (Nasdaq: HNAB)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.